Evidence map›Paper›PMID 39530749›Full record

ArticleCancer research communications2024

The Capicua C1 Domain Is Required for Full Activity of the CIC::DUX4 Fusion Oncoprotein.

Cuyler Luck, Kyle A Jacobs, Ross A Okimoto

Abstract read
In one paragraph

Article in Cancer research communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

  • Update of
    The2024
5 · Who and what money

Authors and funding

3 authors.

Cuyler LuckBiomedical Sciences Graduate Program, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-1150-0057
Kyle A JacobsBiomedical Sciences Graduate Program, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-4411-7855
Ross A OkimotoDepartment of Medicine, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-4467-8476

Funding

Research BaseP30DK063720 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI VAISSE, CHRISTIAN · 2003 to 2019
$21.8M
Restorative practice in repairing harm and promoting safe and inclusive practices in the laboratory.T32GM136547 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Adrian Erlebacher, Anita Sil · 2020 to 2026
$4.5M
Therapeutic degradation of Capicua (CIC) fused oncoproteins in undifferentiated sarcomasR37CA255453 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Ross Okimoto · 2021 to 2026
$2.7M
BD FACSAria Fusion Cell SorterS10OD021822 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LEE, MICHAEL R. · 2016 to 2016
$573k
Leveraging Retained Partner Gene Function to Effectively Target CIC-rearranged Fusion OncoproteinsF31CA287493 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LUCK, CUYLER · 2024 to 2025
$92k
NCI NIH HHS F31 CA287493NCI NIH HHS R37 CA255453NIDDK NIH HHS P30 DK063720NIGMS NIH HHS T32 GM136547NIH HHS S10 OD021822
6 · The paper itself

Abstract

abstractRearrangements between genes can yield neomorphic fusions that drive oncogenesis. Fusion oncogenes are made up of fractional segments of the partner genes that comprise them, with each partner potentially contributing some of its own function to the nascent fusion oncoprotein. Clinically, fusion oncoproteins driving one diagnostic entity are typically clustered into a single molecular subset and are often treated a similar fashion. However, knowledge of where specific fusion breakpoints occur in partner genes, and the resulting retention of functional domains in the fusion, is an important determinant of fusion oncoprotein activity and may differ between patients. This study investigates these phenomena through the example of capicua (CIC)::double homeobox 4 (DUX4), a fusion between transcriptional repressor CIC and DUX4 genes, which drives an aggressive subset of undifferentiated round cell sarcoma. Using a harmonized dataset of more than 100 patient fusion breakpoints from the literature, we show that most bona fide CIC::DUX4 fusions retain the C1 domain, which is known to contribute to DNA binding by wild-type CIC. Mechanistically, deletion or mutation of the C1 domain reduces, but does not eliminate, the activation of CIC target genes by CIC::DUX4. We also find that expression of C1-deleted CIC::DUX4 is capable of exerting intermediate transformation-related phenotypes compared with those imparted by full-length CIC::DUX4 but was not sufficient for tumorigenesis in a subcutaneous mouse model. In summary, our results suggest a supercharging role for the C1 domain in the activity of CIC::DUX4. SIGNIFICANCE: We show in mammalian settings that the capicua C1 functional domain is a supercharger for CIC::DUX4, a poorly studied fusion oncoprotein which drives a rare sarcoma with dismal outcomes.

Indexed as

Oncogene Proteins, FusionAnimalsHomeodomain ProteinsHumansMiceProtein DomainsRepressor ProteinsSarcomaCIC-DUX4 fusion protein, humanHomeodomain ProteinsOncogene Proteins, FusionRepressor Proteins

Identifiers

PMID39530749
PMCPMC11626509

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.